TOP TEN perturbations for NM_000099 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000099
Selected probe(set): 201360_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000099 (201360_at) across 5339 perturbations tested by GENEVESTIGATOR:

kidney transplantation study 14 (12 week) / normal B-cell (CD19+) sample

Relative Expression (log2-ratio):3.943287
Number of Samples:3 / 5
Experimental kidney transplantation study 14 (12 week)
CD19+ B-cell samples derived from kidney transplant patients 12 weeks post-transplantation. Samples were collected 12 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal B-cell (CD19+) sample
CD19+ B-cell samples derived from healthy control subjects.

B-ALL study 1 (hyperdiploid) / normal bone marrow sample

Relative Expression (log2-ratio):-3.8700514
Number of Samples:40 / 74
Experimental B-ALL study 1 (hyperdiploid)
Bone marrow samples of patients with hyperdiploid B-ALL (hyperdiploid karyotype).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

B-CLL study 9 (CD19+; CD5+; Wnt3a) / Wnt3a study 1

Relative Expression (log2-ratio):3.5346127
Number of Samples:6 / 4
Experimental B-CLL study 9 (CD19+; CD5+; Wnt3a)
CD19+ CD5+ B-cell samples from subjects with chronic lymphocytic leukemia (CLL) and treated with Wnt3a for 48 hours. It is not clear whether the concentration of Wnt3a was 5ng/ml or 50ng/ml. B-cells were isolated from peripheral blood mononuclear cells. Samples were collected from predominantly chemotherapy-naive patients representing the broad spectrum of CLL clinical heterogeneity, based on established prognostic risk factors (ZAP70 expression; degree of somatic hypermutation in the variable region of the immunoglobulin heavy chain [IGHV] gene; presence of specific CLL-associated cytogenetic abnormalities). All tumor samples were comprised of more then 95% tumor purity.
Control Wnt3a study 1
CD19+ B-cell samples from normal control subjects and treated with Wnt3a for 48 hours. It is not clear whether the concentration of Wnt3a was 5ng/ml or 50ng/ml. B-cells were isolated from peripheral blood mononuclear cells and cultured in B-cell media.

glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):3.4633398
Number of Samples:2 / 4
Experimental glioma study 17 ( small cell glioblastoma; unsorted)
Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ? 3 years old males.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

B-CLL study 9 (CD19+; CD5+; untreated) / untreated normal B-cell sample (CD19+)

Relative Expression (log2-ratio):3.4576397
Number of Samples:3 / 2
Experimental B-CLL study 9 (CD19+; CD5+; untreated)
Untreated CD19+ CD5+ B-cell samples from subjects with chronic lymphocytic leukemia (CLL) and cultured in B-cell media. B-cells were isolated from peripheral blood mononuclear cells. Samples were collected from predominantly chemotherapy-naive patients representing the broad spectrum of CLL clinical heterogeneity, based on established prognostic risk factors (ZAP70 expression; degree of somatic hypermutation in the variable region of the immunoglobulin heavy chain [IGHV] gene; presence of specific CLL-associated cytogenetic abnormalities). All tumor samples were comprised of more then 95% tumor purity.
Control untreated normal B-cell sample (CD19+)
Untreated CD19+ B-cell samples from normal control subjects and cultured in B-cell media. B-cells were isolated from peripheral blood mononuclear cells.

c-ALL/pre-B-ALL study 1 / normal bone marrow sample

Relative Expression (log2-ratio):-3.2814684
Number of Samples:233 / 74
Experimental c-ALL/pre-B-ALL study 1
Bone marrow samples of patients with c-ALL/pre-B-ALL (without t(9;22)(q34,q11)/BCR-ABL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

glioma study 16 (LN-319) / normal astrocyte sample

Relative Expression (log2-ratio):3.2530203
Number of Samples:2 / 3
Experimental glioma study 16 (LN-319)
Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37?C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):3.1745014
Number of Samples:2 / 4
Experimental glioma study 17 (glioblastoma; unsorted)
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.0998526
Number of Samples:70 / 74
Experimental precursor-B-ALL study 1 (t(11q23))
Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

ALL study 2 (33d) / ALL study 2 (0d)

Relative Expression (log2-ratio):3.06738
Number of Samples:58 / 129
Experimental ALL study 2 (33d)
Bone marrow samples from children with de novo acute lymphoblastic leukemia. Samples were taken 33 days after remission-induction therapy (RIT).
Control ALL study 2 (0d)
Bone marrow samples from children with de novo acute lymphoblastic leukemia. Samples were taken before remission-induction therapy (RIT).